特拉唑嗪

Description

terazosin · CAS 63590-64-7 · C19H25N5O4. UNII 8L5014XET7. Melting Point: 271-274; Melting Point: 273 °C; Solubility: 1.50e+00 g/L.

Identification

CAS Registry Number	63590-64-7
PubChem CID	5401
Molecular formula	C19H25N5O4
IUPAC name	[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
UNII (FDA)	8L5014XET7

Computed Descriptors

Molecular Weight	387.4
XLogP3	1.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	4
Exact Mass	387.19065430
Monoisotopic Mass	387.19065430
Topological Polar Surface Area	103
Heavy Atom Count	28
Formal Charge	0

Physical & Chemical Properties

Melting Point	271-274
Melting Point	273 °C
Solubility	1.50e+00 g/L
LogP	1.14

Physical description & handling notes

• Solid
• 189.79 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
• 180.8 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
• 194.24 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
• 192.56 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
• Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocker.

Regulatory Status

GHS notification summary	2.3% (1 / 44)

GHS Hazard Classification

GHS notification summary	2.3% (1 / 44)
Reported hazard statements	H302 (97.7%)

Documented Uses

• Use (kg; approx.) in Germany (2009): >75
• Consumption (g per capita; approx.) in Germany (2009): 0.000916
• Consumption (g per capita) in the USA (2002): 0.00144
• Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension.
• Terazosin was approved by the Food and Drug Administration (FDA) in 1987 initially as a treatment for hypertension. Later, in 1993, it was approved as a treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. The role of pharmacologic therapy in distal urinary tract stones is currently a focus of research, with terazosin and other alpha-1 antagonists under consideration for potential therapeutic value in addition to its traditionally accepted symptomatic relief effects.
• Terazosin is a nonselective alpha-1 adrenergic antagonist used in the therapy of hypertension and benign prostatic hypertrophy. Terazosin therapy is associated with a low rate of transient serum aminotransferase elevations and to rare instances of clinically apparent acute liver injury.

Synonyms

terazosin; 63590-64-7; Terazosine; Fosfomic; Terazosina; Blavin; Flumarc; Terazosinum; Terazosabb; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; Hytrinex; Vicard; 8L5014XET7; CHEBI:9445; DTXSID3023639; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-

Frequently Asked Questions

What are the CAS number and molecular formula of terazosin?

CAS 63590-64-7; molecular formula C19H25N5O4; molecular weight — g/mol.

What other names is terazosin known by?

terazosin, 63590-64-7, Terazosine, Fosfomic, Terazosina, Blavin.

Is terazosin classified as hazardous?

2.3% of GHS notifications report no hazard classification (1 of 44).

What are the key physical properties of terazosin?

Melting Point: 271-274; Melting Point: 273 °C; Solubility: 1.50e+00 g/L; LogP: 1.14.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.